Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.

Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T.

J Am Soc Nephrol. 2019 Aug;30(8):1523-1533. doi: 10.1681/ASN.2018121261. Epub 2019 Jul 19.

PMID:
31324734
2.

Effect of Intensive and Standard Clinic-Based Hypertension Management on the Concordance Between Clinic and Ambulatory Blood Pressure and Blood Pressure Variability in SPRINT.

Ghazi L, Pajewski NM, Rifkin DE, Bates JT, Chang TI, Cushman WC, Glasser SP, Haley WE, Johnson KC, Kostis WJ, Papademetriou V, Rahman M, Simmons DL, Taylor A, Whelton PK, Wright JT, Bhatt UY, Drawz PE.

J Am Heart Assoc. 2019 Jul 16;8(14):e011706. doi: 10.1161/JAHA.118.011706. Epub 2019 Jul 15.

3.

Attended Versus Unattended Automated Office Blood Pressure: A Systematic Review and Meta-analysis.

Andreadis EA, Thomopoulos C, Geladari CV, Papademetriou V.

High Blood Press Cardiovasc Prev. 2019 Aug;26(4):293-303. doi: 10.1007/s40292-019-00329-1. Epub 2019 Jul 9.

PMID:
31290085
4.

Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART.

Upadhya B, Rocco MV, Pajewski NM, Morgan T, Blackshear J, Hundley WG, Oparil S, Soliman EZ, Cohen DL, Hamilton CA, Cho ME, Kostis WJ, Papademetriou V, Rodriguez CJ, Raj DS, Townsend R, Vasu S, Zamanian S, Kitzman DW; SPRINT Research Group * .

Hypertension. 2019 Jul 1:HYPERTENSIONAHA11913073. doi: 10.1161/HYPERTENSIONAHA.119.13073. [Epub ahead of print]

PMID:
31256724
5.

Renal Sympathetic Denervation in Isolated Systolic Hypertension.

Doumas M, Papademetriou V, Tsioufis C.

Hypertension. 2019 Aug;74(2):255-256. doi: 10.1161/HYPERTENSIONAHA.119.13168. Epub 2019 Jun 17. No abstract available.

PMID:
31203724
6.

Morning Surge and Peak Morning Ambulatory Blood Pressure Versus Automated Office Blood Pressure in Predicting Cardiovascular Disease.

Andreadis EA, Geladari CV, Angelopoulos ET, Kolyvas GN, Papademetriou V.

High Blood Press Cardiovasc Prev. 2019 Jun;26(3):209-215. doi: 10.1007/s40292-019-00315-7. Epub 2019 Apr 15.

PMID:
30989620
7.

Primary aldosteronism: novel insights.

Stavropoulos K, Imprialos K, Papademetriou V, Faselis C, Tsioufis K, Dimitriadis K, Doumas M.

Curr Hypertens Rev. 2019 Apr 15. doi: 10.2174/1573402115666190415155512. [Epub ahead of print]

PMID:
30987572
8.

Pharmacological Management of Diabetic Nephropathy.

Papademetriou V, Alataki S, Stavropoulos K, Papadopoulos C, Bakogiannis K, Tsioufis K.

Curr Vasc Pharmacol. 2019 Apr 5. doi: 10.2174/1570161117666190405164749. [Epub ahead of print]

PMID:
30961500
9.

Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations.

Magkas N, Tsioufis C, Thomopoulos C, Dilaveris P, Georgiopoulos G, Sanidas E, Papademetriou V, Tousoulis D.

J Clin Hypertens (Greenwich). 2019 May;21(5):546-554. doi: 10.1111/jch.13521. Epub 2019 Mar 22. Review.

10.

Insomnia and hypertension: A misty landscape.

Stavropoulos K, Imprialos KP, Doumas M, Karagiannis A, Papademetriou V.

J Clin Hypertens (Greenwich). 2019 Jun;21(6):835-837. doi: 10.1111/jch.13519. Epub 2019 Mar 15. No abstract available.

11.

Now That Renal Denervation Works, How Do We Proceed?

Papademetriou V, Stavropoulos K, Doumas M, Tsioufis K.

Circ Res. 2019 Mar;124(5):693-695. doi: 10.1161/CIRCRESAHA.119.314695. No abstract available.

PMID:
30817252
12.

The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

Papademetriou V, Toumpourleka M, Imprialos KP, Alataki S, Manafis A, Stavropoulos K.

Curr Pharm Des. 2018;24(46):5517-5524. doi: 10.2174/1381612825666190219141326.

PMID:
30806305
13.

Labile hypertension: a new disease or a variability phenomenon?

Sanidas E, Grassos C, Papadopoulos DP, Velliou M, Tsioufis K, Mantzourani M, Perrea D, Iliopoulos D, Barbetseas J, Papademetriou V.

J Hum Hypertens. 2019 Jun;33(6):436-443. doi: 10.1038/s41371-018-0157-8. Epub 2019 Jan 15. Review.

PMID:
30647464
14.

The clinical value of automated office blood pressure: What is the latest evidence on attended vs unattended automated readings in clinical practice?

Andreadis EA, Geladari CV, Angelopoulos ET, Papademetriou V.

J Clin Hypertens (Greenwich). 2019 Feb;21(2):156-158. doi: 10.1111/jch.13455. Epub 2018 Dec 14. No abstract available.

15.

PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.

Ginsberg C, Craven TE, Chonchol MB, Cheung AK, Sarnak MJ, Ambrosius WT, Killeen AA, Raphael KL, Bhatt UY, Chen J, Chertow GM, Freedman BI, Oparil S, Papademetriou V, Wall BM, Wright CB, Ix JH, Shlipak MG; SPRINT Research Group.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1816-1824. doi: 10.2215/CJN.05390518. Epub 2018 Nov 13.

PMID:
30425104
16.

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25.

PMID:
30361335
17.

Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?

Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Riessen E, Shapiro B, Stergiou GS, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V.

J Clin Hypertens (Greenwich). 2018 Nov;20(11):1644-1645. doi: 10.1111/jch.13395. Epub 2018 Oct 17. No abstract available.

18.

Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.

Papademetriou V, Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Dimitriadis K, Tsioufis K.

Curr Pharm Des. 2018;24(31):3647-3653. doi: 10.2174/1381612824666181010124657.

PMID:
30317985
19.

Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis.

Kataoka Y, Delacroix S, Sidharta S, Andrews J, Nicholls SJ, Tsioufis CP, Papademetriou V, Worthley SG.

Int J Nephrol Renovasc Dis. 2018 Sep 27;11:259-266. doi: 10.2147/IJNRD.S161313. eCollection 2018.

20.

Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study.

Papademetriou V, Tsioufis C, Chung A, Geladari C, Andreadis EA.

J Clin Hypertens (Greenwich). 2018 Oct;20(10):1411-1416. doi: 10.1111/jch.13371. Epub 2018 Oct 1.

21.

The Reply.

Papademetriou V.

Am J Med. 2018 Jul;131(7):e317. doi: 10.1016/j.amjmed.2018.01.051. No abstract available.

PMID:
29909847
22.

The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".

Sanidas E, Papadopoulos DP, Velliou M, Tsioufis K, Mantzourani M, Iliopoulos D, Perrea D, Barbetseas J, Papademetriou V.

Am J Hypertens. 2018 Aug 3;31(9):961-969. doi: 10.1093/ajh/hpy087.

PMID:
29788148
23.
24.

Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study.

Kasiakogias A, Tsioufis C, Dimitriadis K, Konstantinidis D, Koumelli A, Leontsinis I, Andrikou E, Vogiatzakis N, Marinaki S, Petras D, Fragoulis C, Konstantinou K, Papademetriou V, Tousoulis D.

J Hum Hypertens. 2018 Jul;32(7):487-493. doi: 10.1038/s41371-018-0065-y. Epub 2018 May 1.

PMID:
29713047
25.

Attended and Unattended Automated Office Blood Pressure Measurements Have Better Agreement With Ambulatory Monitoring Than Conventional Office Readings.

Andreadis EA, Geladari CV, Angelopoulos ET, Savva FS, Georgantoni AI, Papademetriou V.

J Am Heart Assoc. 2018 Apr 7;7(8). pii: e008994. doi: 10.1161/JAHA.118.008994.

26.

Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.

Papademetriou V, Geladari E.

Cardiovasc Hematol Disord Drug Targets. 2018;18(2):127-133. doi: 10.2174/1871529X18666180405102658.

PMID:
29618313
27.

Is statin therapy safe and effective in patients with chronic Kidney disease?

Raman VK, Geladari E, Papademetriou V.

Curr Pharm Des. 2018 Jan 9. doi: 10.2174/1381612824666180110100103. [Epub ahead of print]

PMID:
29318962
28.

Human Immunodeficiency Virus Infection And Hypertension. Is There a Connection?

Sanidas E, Papadopoulos DP, Velliou M, Tsioufis K, Barbetseas J, Papademetriou V.

Am J Hypertens. 2018 Mar 10;31(4):389-393. doi: 10.1093/ajh/hpx208.

PMID:
29220484
29.

From 'essential' hypertension to intensive blood pressure lowering: the pros and cons of lower target values.

L├╝scher TF, Kjeldsen SE, Mancia G, Papademetriou V.

Eur Heart J. 2017 Nov 21;38(44):3258-3271. doi: 10.1093/eurheartj/ehx643. No abstract available.

PMID:
29177419
30.
31.

Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension.

Doumas M, Tsioufis C, Fletcher R, Amdur R, Faselis C, Papademetriou V.

J Am Heart Assoc. 2017 Nov 3;6(11). pii: e007131. doi: 10.1161/JAHA.117.007131.

32.

SPYRAL HTN-OFF MED study: Renal denervation in the spiral orbits of current results and future studies.

Tsioufis C, Dimitriadis K, Papademetriou V, Tousoulis D.

Hellenic J Cardiol. 2017 Sep - Oct;58(5):320-321. doi: 10.1016/j.hjc.2017.09.012. Epub 2017 Oct 19. No abstract available.

33.

Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.

Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK; SPRINT Research Group.

Circulation. 2018 Jan 9;137(2):134-143. doi: 10.1161/CIRCULATIONAHA.117.030848. Epub 2017 Oct 11.

34.

Air pollution and arterial hypertension. A new risk factor is in the air.

Sanidas E, Papadopoulos DP, Grassos H, Velliou M, Tsioufis K, Barbetseas J, Papademetriou V.

J Am Soc Hypertens. 2017 Nov;11(11):709-715. doi: 10.1016/j.jash.2017.09.008. Epub 2017 Sep 27. Review.

PMID:
28989071
35.

Reply.

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, de Leeuw PW, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B.

J Hypertens. 2017 Nov;35(11):2327-2328. doi: 10.1097/HJH.0000000000001526. No abstract available.

36.

Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial.

Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, Cheung AK, Cohen D, Freedman BI, Hawfield AT, Killeen AA, Kimmel PL, Lash J, Papademetriou V, Rahman M, Rastogi A, Servilla K, Townsend RR, Wall B, Whelton PK; SPRINT Research Group.

Ann Intern Med. 2017 Sep 19;167(6):375-383. doi: 10.7326/M16-2966. Epub 2017 Sep 5.

PMID:
28869987
37.

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.

Papademetriou V, Nylen ES, Doumas M, Probstfield J, Mann JFE, Gilbert RE, Gerstein HC.

Am J Med. 2017 Dec;130(12):1465.e27-1465.e39. doi: 10.1016/j.amjmed.2017.05.047. Epub 2017 Aug 31.

PMID:
28842165
38.

Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.

Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V; SPRINT Research Group.

Diabetes Care. 2017 Aug 9. pii: dc170885. doi: 10.2337/dc17-0885. [Epub ahead of print]

39.

Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial).

Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Raj D, Riessen E, Shapiro B, Stergiou GS, Townsend RR, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V; SPRINT Research Group*.

Hypertension. 2017 Oct;70(4):751-758. doi: 10.1161/HYPERTENSIONAHA.117.09788. Epub 2017 Jul 31.

40.

APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial.

Freedman BI, Rocco MV, Bates JT, Chonchol M, Hawfield AT, Lash JP, Papademetriou V, Sedor JR, Servilla K, Kimmel PL, Wall BM, Pajewski NM; SPRINT Research Group.

Kidney Int Rep. 2017 Jul;2(4):713-720. doi: 10.1016/j.ekir.2017.03.008. Epub 2017 Mar 31.

41.

The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?

Papademetriou M, Athyros VG, Geladari E, Doumas M, Tsioufis C, Papademetriou V.

Curr Vasc Pharmacol. 2018;16(3):254-268. doi: 10.2174/1570161115666170621081638. Review.

PMID:
28676027
42.

Expertise: no longer a sine qua non for guideline authors?

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B, de Leeuw PW.

J Hypertens. 2017 Aug;35(8):1564-1566. doi: 10.1097/HJH.0000000000001435.

43.

Expertise: No Longer a Sine Qua Non for Guideline Authors?

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B.

Hypertension. 2017 Aug;70(2):235-237. doi: 10.1161/HYPERTENSIONAHA.117.09470. Epub 2017 Jun 26. No abstract available.

44.

Geometric patterns of left ventricular hypertrophy: Is geometry alone to be blamed?

Papademetriou V.

Hellenic J Cardiol. 2017 Mar - Apr;58(2):143-145. doi: 10.1016/j.hjc.2017.05.010. Epub 2017 Jun 23. No abstract available.

45.

Effects of Intensive BP Control in CKD.

Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J; SPRINT Research Group.

J Am Soc Nephrol. 2017 Sep;28(9):2812-2823. doi: 10.1681/ASN.2017020148. Epub 2017 Jun 22.

46.

Corrigendum to "Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the cardiovascular health study" [Int. J. Cardiol. 235 (2017) 11-16].

Tsimploulis A, Sheriff HM, Lam PH, Dooley DJ, Anker MS, Papademetriou V, Fletcher RD, Faselis C, Fonarow GC, Deedwania P, White M, Valentova M, Blackman MR, Banach M, Morgan CJ, Alagiakrishnan K, Allman RM, Aronow WS, Anker SD, Ahmed A.

Int J Cardiol. 2017 Jul 1;238:181. doi: 10.1016/j.ijcard.2017.04.072. Epub 2017 May 6. No abstract available.

PMID:
28487149
47.

Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?

Tsioufis C, Iliakis P, Kasiakogias A, Konstantinidis D, Lovic D, Petras D, Doumas M, Tsiamis E, Papademetriou V, Tousoulis D.

Curr Vasc Pharmacol. 2017;16(1):30-43. doi: 10.2174/1570161115666170428124756. Review.

PMID:
28462724
48.

Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?

Tsioufis C, Dimitriadis K, Kordalis A, Doumas M, Konstantinidis D, Kalos T, Mahfoud F, Papademetriou V, Tousoulis D.

Curr Vasc Pharmacol. 2017;16(1):66-69. doi: 10.2174/1570161115666170426151649. Review.

PMID:
28462714
49.

Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?

Raman VK, Tsioufis C, Doumas M, Papademetriou V.

Curr Treat Options Cardiovasc Med. 2017 May;19(5):39. doi: 10.1007/s11936-017-0536-4. Review.

PMID:
28455809
50.

Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis.

Vogiatzakis N, Tsioufis C, Georgiopoulos G, Thomopoulos C, Dimitriadis K, Kasiakogias A, Konstantinidis D, Kalos T, Mahfoud F, Doumas M, Papademetriou V, Tousoulis D.

J Hypertens. 2017 Sep;35(9):1750-1757. doi: 10.1097/HJH.0000000000001391.

PMID:
28445207

Supplemental Content

Loading ...
Support Center